Business context and reporting period
Filing identity: The supplied filing is for AFH Acquisition X, Inc., not Bone Biologics Corp as identified in the request metadata. AFH describes itself as a development-stage, shell/blank-check company seeking a business combination. This unaudited Form 10-Q covers the quarter and nine months ended July 31, 2013.
The company reported no active operations beyond seeking acquisition candidates and said it was not negotiating with a target as of the financial statement date. It was wholly owned by AFH Holding & Advisory, LLC.
Financial results and liquidity
| Metric | Period / date | Reported value |
|---|---|---|
| Revenue | Three and nine months ended July 31, 2013 | $0 |
| Net loss | Three months ended July 31, 2013; 2012 comparable | $(1,085); $(1,088) |
| Net loss | Nine months ended July 31, 2013; 2012 comparable | $(4,176); $(4,594) |
| Total expenses before franchise tax | Nine months ended July 31, 2013 | $3,776 |
| Cash and cash equivalents | July 31, 2013; October 31, 2012 | $410; $500 |
| Total liabilities | July 31, 2013; October 31, 2012 | $39,185; $35,099 |
| Due to parent | July 31, 2013; October 31, 2012 | $35,999; $30,605 |
| Accumulated deficit | July 31, 2013 | $63,775 |
| Operating cash flow | Nine months ended July 31, 2013; 2012 comparable | $(5,484); $0 |
| Financing cash flow | Nine months ended July 31, 2013 | $5,394, entirely reported as a parent advance |
Cash declined by $90 during the nine-month period. The company reported negative working capital of $38,775. No operating margin is meaningful because there was no revenue; the filing does not provide a debt balance separate from the amount due to the parent. No interest or income taxes were paid during the periods presented.
Changes, outlook, and risks
- Nine-month net loss improved by $418 versus the comparable 2012 period; quarterly net loss was nearly unchanged. Nine-month operating cash outflow was $5,484, compared with no net operating cash flow in 2012.
- The company said it would rely on common-stock issuance and additional shareholder capital contributions to fund administrative expenses while pursuing an acquisition. It gave no specific forecast or financing commitment.
- Management and the notes state there is substantial doubt about the company’s ability to continue as a going concern. The filing cites recurring losses, accumulated deficit, and dependence on raising capital or acquiring a marketable company. The financial statements include no adjustments that might be required if the company cannot continue as a going concern.
- Parent advances have no stated repayment terms. The company cautioned that an acquisition could substantially dilute existing shareholders and that future securities issuance could depress the share price; there is no assurance that equity funding or a business combination will be achieved.
- Management reported disclosure controls were effective and no significant changes to internal controls during the quarter. The filing reported no legal proceedings, unregistered equity sales, or defaults upon senior securities.
Important facts for investors to verify
- Confirm the filing belongs to the intended issuer: the document names AFH Acquisition X, Inc., not Bone Biologics Corp.
- Verify the status of any subsequent business-combination discussions and the company’s current shell-company status.
- Assess the availability and terms of future funding, including the parent advances and the company’s going-concern warning.
- Review potential dilution and transaction terms if a business combination or securities offering is pursued.